AVI Biopharma, Inc. (AVII) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
AVI Biopharma, Inc. (NASDAQ: AVII) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $15.5 million versus the consensus estimate of $11.65 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Capri Holdings Limited (CPRI) Tops Q2 EPS by 21c; offers guidance
- Federal Realty Inv. Trust (FRT) Tops Q3 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
